Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute’s innovative drug development initiative-Group 3 pulmonary hypertension

By sjmartinez • July 1, 2022

Nikkho SM, Richter MJ, Shen E, Abman SH, Antoniou K, Chung J, Fernandes P, Hassoun P, Lazarus HM, Olschewski H, Piccari L, Psotka M, Saggar R, Shlobin OA, Stockbridge N, Vitulo P, Vizza CD, Wort SJ, Nathan SD. Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension. Pulm Circ. 2022 Jul 1;12(3):e12127. doi: 10.1002/pul2.12127. PMID: 36016668; PMCID: PMC9395696.

Tags: Epidemiology, interstitial lung disease, prognosis, Publications, pulmonary hypertension, Pulmonary, Critical Care & Sleep Medicine, symptom assessment and management

A review of silicosis and other silica-related diseases in the engineered stone countertop processing industry

Fazio JC, Viragh K, Houlroyd J, Gandhi SA. A review of silicosis and other silica-related diseases in the engineered stone countertop processing industry. J Occup[...]

The role of prenatal maternal sex steroid hormones in weight and adiposity at birth and growth trajectories during infancy

Meng Y, Thornburg LL, Dreisbach C, Orzolek C, Kautz A, Murphy HR, Rivera-Núñez Z, Wang C, Miller RK, O'Connor TG, Barrett ES. The role of[...]

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer

Herbst RS, John T, Grohé C, Goldman JW, Kato T, Laktionov K, Bonanno L, Tiseo M, Majem M, Dómine M, Ahn MJ, Kowalski DM, Pérol[...]